Day One Biopharmaceuticals, Inc. (DAWN) 10-Year Financial Performance & Capital Metrics

DAWN • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsSolid Tumor Oncology

AboutDay One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Show more

Revenue $131M
EBITDA -$215M -4.6%
Net Income -$95M +49.5%
EPS (Diluted) -1.02 +57.0%
Gross Margin 95.98%
EBITDA Margin -164.1%
Operating Margin -165.65%
Net Margin -72.81%
ROE -22.49% +59.6%
ROIC -65.63% +22.8%
Debt/Equity 0.01 +339.8%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Company is almost debt free
✓Momentum leader: RS Rating 85 (top 15%)

✗Weaknesses

✗Negative free cash flow
✗Shares diluted 17.4% in last year
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM31.11%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-80.04%

EPS CAGR

10Y-

5Y-

3Y-

TTM-51.4%

ROCE

10Y Avg-50.49%

5Y Avg-48.82%

3Y Avg-53.12%

Latest-50.77%

Peer Comparison

Solid Tumor Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
TLXTelix Pharmaceuticals Limited	2.49B	7.43	53.07	55.85%	3.98%	15.63%	0.36%	1.02
EXELExelixis, Inc.	12.18B	45.44	25.82	18.49%	29.63%	31.37%	5.2%	0.09
BBOTBridgeBio Oncology Therapeutics Inc.	919.87M	11.50	25			-25.73%
INBXInhibrx Biosciences, Inc.	1.04B	71.80	0.62	-88.89%	-110.78%	-421.09%		0.06
NUVBNuvation Bio Inc.	2.1B	6.14	-2.91		-8.13%	-66.74%		0.02
RLAYRelay Therapeutics, Inc.	1.32B	7.63	-3.23	-60.83%	-26.71%	-48.97%		0.06
ORICORIC Pharmaceuticals, Inc.	1.12B	11.52	-6.30			-33.24%		0.01
ZLABZai Lab Limited	2.09B	18.82	-7.24	49.59%	-46.83%	-27.21%		0.18

Profit & Loss

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	131.16M
Revenue Growth %	-	-	-	-	-	-
Cost of Goods Sold+	0	155K	199K	531K	383K	5.28M
COGS % of Revenue	-	-	-	-	-	0.04%
Gross Profit+	0	-155K	-199K	-531K	-383K	125.88M
Gross Margin %	-	-	-	-	-	0.96%
Gross Profit Growth %	-	-	-0.28%	-1.67%	0.28%	329.67%
Operating Expenses+	14.9M	13.63M	72.54M	146.38M	205.68M	343.15M
OpEx % of Revenue	-	-	-	-	-	2.62%
Selling, General & Admin	1.01M	4.53M	28.96M	60.76M	75.16M	115.45M
SG&A % of Revenue	-	-	-	-	-	0.88%
Research & Development	13.9M	9.1M	43.58M	85.62M	130.52M	227.7M
R&D % of Revenue	-	-	-	-	-	1.74%
Other Operating Expenses	0	0	0	0	0	0
Operating Income+	-14.9M	-13.78M	-72.74M	-146.91M	-206.06M	-217.27M
Operating Margin %	-	-	-	-	-	-1.66%
Operating Income Growth %	-	0.08%	-4.28%	-1.02%	-0.4%	-0.05%
EBITDA+	0	-13.63M	-72.54M	-146.38M	-205.68M	-215.24M
EBITDA Margin %	-	-	-	-	-	-1.64%
EBITDA Growth %	-	-	-4.32%	-1.02%	-0.41%	-0.05%
D&A (Non-Cash Add-back)	14.9M	155K	199K	531K	383K	2.03M
EBIT	-14.91M	-43.81M	-72.75M	-142.18M	-188.92M	-88.35M
Net Interest Income+	-2.08M	-30K	4K	4.75M	17.19M	19.7M
Interest Income	0	0	4K	4.75M	17.19M	19.7M
Interest Expense	2.08M	30K	0	0	0	0
Other Income/Expense	-2.08M	-30.06M	-11K	4.73M	17.15M	128.92M
Pretax Income+	-16.98M	-43.84M	-72.75M	-142.18M	-188.92M	-88.35M
Pretax Margin %	-	-	-	-	-	-0.67%
Income Tax+	0	0	0	0	0	7.14M
Effective Tax Rate %	0.74%	0.92%	0.97%	1%	1%	1.08%
Net Income+	-12.63M	-40.51M	-70.64M	-142.18M	-188.92M	-95.5M
Net Margin %	-	-	-	-	-	-0.73%
Net Income Growth %	-	-2.21%	-0.74%	-1.01%	-0.33%	0.49%
Net Income (Continuing)	-16.98M	-43.84M	-72.75M	-142.18M	-188.92M	-95.5M
Discontinued Operations	0	0	0	0	0	0
Minority Interest	5.49M	5.7M	0	0	0	0
EPS (Diluted)+	-0.24	-0.65	-1.14	-2.02	-2.37	-1.02
EPS Growth %	-	-1.71%	-0.75%	-0.77%	-0.17%	0.57%
EPS (Basic)	-0.24	-0.65	-1.14	-2.02	-2.37	-1.02
Diluted Shares Outstanding	61.93M	61.93M	61.95M	65.47M	79.77M	93.62M
Basic Shares Outstanding	61.93M	61.93M	61.95M	65.47M	79.77M	93.62M
Dividend Payout Ratio	-	-	-	-	-	-

Balance Sheet

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	27.34M	45.07M	289.37M	347.87M	375.27M	562.33M
Cash & Short-Term Investments	27.33M	43.73M	284.31M	342.27M	366.35M	531.72M
Cash Only	27.33M	43.73M	284.31M	85.26M	230.78M	124.97M
Short-Term Investments	0	0	0	257.01M	135.56M	406.75M
Accounts Receivable	0	0	0	0	0	13.88M
Days Sales Outstanding	-	-	-	-	-	38.61
Inventory	0	0	0	0	0	3.32M
Days Inventory Outstanding	-	-	-	-	-	229.62
Other Current Assets	0	1.26M	1.01M	1.01M	2.35M	4.37M
Total Non-Current Assets+	0	590K	453K	1.19M	774K	20.46M
Property, Plant & Equipment	0	483K	284K	719K	560K	4.71M
Fixed Asset Turnover	-	-	-	-	-	27.87x
Goodwill	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	15.63M
Long-Term Investments	0	0	0	0	0	0
Other Non-Current Assets	0	107K	169K	469K	214K	121K
Total Assets+	27.34M	45.66M	289.82M	349.06M	376.05M	582.79M
Asset Turnover	-	-	-	-	-	0.23x
Asset Growth %	-	0.67%	5.35%	0.2%	0.08%	0.55%
Total Current Liabilities+	2.02M	2M	8.66M	16.61M	29.51M	73.45M
Accounts Payable	69K	202K	1.74M	260K	2.58M	3.26M
Days Payables Outstanding	-	475.68	3.2K	178.72	2.45K	225.54
Short-Term Debt	0	0	204K	405K	408K	10K
Deferred Revenue (Current)	0	0	0	0	0	1000K
Other Current Liabilities	1.49M	27K	104K	9.82M	17.36M	54.68M
Current Ratio	13.53x	22.58x	33.43x	20.94x	12.72x	7.66x
Quick Ratio	13.53x	22.58x	33.43x	20.94x	12.72x	7.61x
Cash Conversion Cycle	-	-	-	-	-	42.69
Total Non-Current Liabilities+	30.5M	204K	16K	408K	0	6.59M
Long-Term Debt	0	0	0	0	0	0
Capital Lease Obligations	0	204K	16K	408K	0	2.59M
Deferred Tax Liabilities	0	0	0	0	0	0
Other Non-Current Liabilities	30.5M	0	0	0	0	761K
Total Liabilities	32.52M	2.2M	8.67M	17.02M	29.51M	80.04M
Total Debt+	0	402K	220K	813K	408K	2.6M
Net Debt	-27.33M	-43.33M	-284.09M	-84.45M	-230.38M	-122.37M
Debt / Equity	-	0.01x	0.00x	0.00x	0.00x	0.01x
Debt / EBITDA	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-
Interest Coverage	-7.18x	-459.40x	-	-	-	-
Total Equity+	-5.19M	43.46M	281.15M	332.04M	346.54M	502.75M
Equity Growth %	-	9.38%	5.47%	0.18%	0.04%	0.45%
Book Value per Share	-0.08	0.70	4.54	5.07	4.34	5.37
Total Shareholders' Equity	-10.67M	37.76M	281.15M	332.04M	346.54M	502.75M
Common Stock	2M	2.64M	6K	7K	9K	10K
Retained Earnings	-12.78M	-56.84M	-127.49M	-269.67M	-458.58M	-554.08M
Treasury Stock	0	0	0	0	0	0
Accumulated OCI	111	0	0	-71K	9K	84K
Minority Interest	5.49M	5.7M	0	0	0	0

Cash Flow

	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.51M	-13.49M	-48.54M	-109.87M	-146.85M	-78.11M
Operating CF Margin %	-	-	-	-	-	-0.6%
Operating CF Growth %	-	-1.99%	-2.6%	-1.26%	-0.34%	0.47%
Net Income	-16.98M	-43.84M	-72.75M	-142.18M	-188.92M	-95.5M
Depreciation & Amortization	0	155K	199K	531K	383K	2.03M
Stock-Based Compensation	111K	526K	13.32M	27.24M	39.34M	48.26M
Deferred Taxes	0	0	0	0	0	0
Other Non-Cash Items	11.91M	30.03M	8M	-2.03M	-7.08M	-59.39M
Working Capital Changes	444K	-357K	2.69M	6.56M	9.42M	26.48M
Change in Receivables	0	0	0	0	0	-13.88M
Change in Inventory	0	0	0	0	0	-3.24M
Change in Payables	14K	132K	1.54M	-1.48M	2.32M	686K
Cash from Investing+	0	-92K	-8M	-255.07M	128.38M	-230.99M
Capital Expenditures	0	-92K	-8M	-26K	-224K	-2.17M
CapEx % of Revenue	-	-	-	-	-	0.02%
Acquisitions	-	-	-	-	-	-
Investments	-	-	-	-	-	-
Other Investing	0	0	0	-255.05K	-3M	35.9M
Cash from Financing+	30.91M	29.98M	297.12M	165.9M	164M	203.29M
Debt Issued (Net)	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-
Other Financing	0	0	318K	4.29M	0	25.11M
Net Change in Cash	-	-	-	-	-	-
Free Cash Flow+	-4.51M	-13.58M	-56.54M	-109.9M	-150.08M	-80.28M
FCF Margin %	-	-	-	-	-	-0.61%
FCF Growth %	-	-2.01%	-3.16%	-0.94%	-0.37%	0.47%
FCF per Share	-0.07	-0.22	-0.91	-1.68	-1.88	-0.86
FCF Conversion (FCF/Net Income)	0.36x	0.33x	0.69x	0.77x	0.78x	0.82x
Interest Paid	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	1.9M

Key Ratios

Metric	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-211.66%	-43.53%	-46.37%	-55.68%	-22.49%
Return on Invested Capital (ROIC)	-	-	-	-90.07%	-84.97%	-65.63%
Gross Margin	-	-	-	-	-	95.98%
Net Margin	-	-	-	-	-	-72.81%
Debt / Equity	-	0.01x	0.00x	0.00x	0.00x	0.01x
Interest Coverage	-7.18x	-459.40x	-	-	-	-
FCF Conversion	0.36x	0.33x	0.69x	0.77x	0.78x	0.82x

Revenue by Segment

	2024
License	73.94M
License Growth	-
Product	57.22M
Product Growth	-

Frequently Asked Questions

Growth & Financials

Day One Biopharmaceuticals, Inc. (DAWN) reported $133.7M in revenue for fiscal year 2024.

Day One Biopharmaceuticals, Inc. (DAWN) grew revenue by 0.0% over the past year. Growth has been modest.

Day One Biopharmaceuticals, Inc. (DAWN) reported a net loss of $151.8M for fiscal year 2024.

Dividend & Returns

Day One Biopharmaceuticals, Inc. (DAWN) has a return on equity (ROE) of -22.5%. Negative ROE indicates the company is unprofitable.

Day One Biopharmaceuticals, Inc. (DAWN) had negative free cash flow of $121.4M in fiscal year 2024, likely due to heavy capital investments.

← Back to Screener